SCHEMBL25201232

SCHEMBL25201232

COC(=O)c1ccc(C=CC(=O)c2ccc(O)cc2)cc1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.75
LMNA P02545 3/20 0.75
NPC1 O15118 1/20 0.75
F3 P13726 3/20 0.74
KMT2A Q03164 5/20 0.72
RAB9A P51151 4/20 0.72
MEN1 O00255 4/20 0.72
P4HB P07237 2/20 0.72
ALDH1A1 P00352 2/20 0.72
CALM1 P0DP23 1/20 0.72
XDH P47989 1/20 0.72
MAOB P27338 4/20 0.69
MAOA P21397 2/20 0.69
POLB P06746 1/20 0.69
ATM Q13315 1/20 0.65
NPSR1 Q6W5P4 1/20 0.65
CA12 O43570 1/20 0.65
CA1 P00915 1/20 0.65
CA2 P00918 1/20 0.65
CA7 P43166 1/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25204220 1.00 MAPT (0.75) MAPTLMNANPC1F3KMT2A
SCHEMBL7911576 0.88 CA1 (0.77) MAPTLMNANPC1F3KMT2A
SCHEMBL3362903 0.87 MAPT (0.75) MAPTLMNANPC1F3KMT2A
SCHEMBL2690446 0.87 MAPT (0.75) MAPTLMNANPC1F3KMT2A
SCHEMBL25223461 0.87 ABCG2 (0.74) MAPTLMNANPC1F3KMT2A
SCHEMBL25211913 0.86 F3 (1.00) MAPTLMNAF3KMT2ARAB9A
SCHEMBL25223420 0.86 F3 (1.00) MAPTLMNAF3KMT2ARAB9A
SCHEMBL10703657 0.86 F3 (1.00) MAPTLMNAF3KMT2ARAB9A
4,4'-Dihydroxychalcone SCHEMBL773588 0.86 F3 (1.00) MAPTLMNAF3KMT2ARAB9A
SCHEMBL25236411 0.86 F3 (1.00) MAPTLMNAF3KMT2ARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260014100-A1 Compositions and Methods for Treating Bleeding and Bleeding Disorders YEWSAVIN INC (US) 2026-01-15 US disclosed
US-12343317-B2 Compositions and methods for treating bleeding and bleeding disorders YewSavin, Inc. (US) 2025-07-01 US disclosed
WO-2024233598-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2024-11-14 WO disclosed
EP-4429763-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS Yewsavin, Inc. (US) 2024-09-18 EP disclosed
US-20230190679-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2023-06-22 US disclosed
WO-2023086388-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2023-05-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260014100-A1 Compositions and Methods for Treating Bleeding and Bleeding Disorders SERPINC1, F2, F13B MAPT 3297/4885LMNA 1180/4885NPC1 1378/4885
US-20230190679-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS SERPINC1, SERPINE1, SERPINH1 MAPT 3512/4885LMNA 1817/4885NPC1 1908/4885
US-12343317-B2 Compositions and methods for treating bleeding and bleeding disorders SERPINC1, SERPINE1, SERPINH1 MAPT 3512/4885LMNA 1817/4885NPC1 1908/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.